Related Experiment Videos
Herceptin: implications for breast cancer management
1Nursing and Midwifery School, University of Glasgow, 68 Oakfield Avenue, Glasgow G12 8LS, UK.
Summary
Traditional chemotherapy offers limited survival benefits for metastatic breast cancer. Novel biological therapies like Herceptin target human epidermal growth factor receptor-2 (HER2), improving outcomes for HER2-overexpressing patients.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Metastatic breast cancer survival shows limited improvement with traditional chemotherapy.
- Novel biological therapies offer targeted approaches for cancer treatment.
- Human epidermal growth factor receptor-2 (HER2) overexpression is linked to aggressive breast cancer and poor prognosis.
Purpose of the Study:
- To evaluate the efficacy and safety of Herceptin, a targeted biological therapy for HER2-overexpressing metastatic breast cancer.
- To determine the role of Herceptin in the treatment landscape of metastatic breast cancer.
Main Methods:
- Clinical trials were conducted to assess Herceptin's tolerability, response rates, and survival impact.
- Investigated the side-effect profile of Herceptin, including cardiotoxicity.
- Explored Herceptin's therapeutic positioning in combination and monotherapy regimens.
Main Results:
- Herceptin demonstrated good tolerability and produced durable objective responses.
- Significant improvements in survival were observed in women with metastatic breast cancer treated with Herceptin.
- Most common side effects were mild to moderate, with manageable cardiotoxicity.
Conclusions:
- Herceptin is an effective targeted therapy for HER2-overexpressing metastatic breast cancer, improving survival.
- Herceptin can be used as first-line therapy with paclitaxel or as subsequent-line monotherapy.
- The development of Herceptin serves as a paradigm for future targeted biological therapies in oncology.